Rocket Pharmaceuticals RCKT
NASDAQ RCKT
$2.27 +0.07 (+2.95%)
As of: Oct 22, 2026 · 2:17 PM EDT

Rocket Pharmaceuticals (RCKT) Non-Current Debt (2014)

Updated

Rocket Pharmaceuticals' Non-Current Debt was $2.55 million in Q4 2014.

Analysis

Rocket Pharmaceuticals (RCKT) Non-Current Debt (2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,169.76 Bn 1,138.35 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 648.06 Bn 567.92 Bn 17.30 Bn 35.80 Bn
3 AbbVie 503.37 Bn 476.48 Bn 12.70 Bn 62.48 Bn
4 Merck 365.39 Bn 319.77 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 303.45 Bn 267.44 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 269.03 Bn 242.72 Bn 12.86 Bn 23.68 Bn
7 Amgen 242.08 Bn 197.48 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 194.88 Bn 169.07 Bn 6.22 Bn 23.83 Bn
9 Pfizer 172.39 Bn 119.04 Bn 10.94 Bn 60.50 Bn
10 Rocket Pharmaceuticals 255.59 Mn -28.11 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 2.55 Mn
API Access

Rocket Pharmaceuticals Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=RCKT&period=max&api_key=YOUR_API_KEY